PL1793844T3 - Zastosowanie [d-meala]3-[etval]4-cyklosporyny do leczenia zakażenia wirusem zapalenia wątroby typu c - Google Patents

Zastosowanie [d-meala]3-[etval]4-cyklosporyny do leczenia zakażenia wirusem zapalenia wątroby typu c

Info

Publication number
PL1793844T3
PL1793844T3 PL05791430T PL05791430T PL1793844T3 PL 1793844 T3 PL1793844 T3 PL 1793844T3 PL 05791430 T PL05791430 T PL 05791430T PL 05791430 T PL05791430 T PL 05791430T PL 1793844 T3 PL1793844 T3 PL 1793844T3
Authority
PL
Poland
Prior art keywords
cyclosporin
treatment
infection
etval
meala
Prior art date
Application number
PL05791430T
Other languages
English (en)
Inventor
Pietro Scalfaro
Jean-Maurice Dumont
Grégoire Vuagniaux
Rolland-Yves Mauvernay
Original Assignee
Debiopharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Sa filed Critical Debiopharm Sa
Publication of PL1793844T3 publication Critical patent/PL1793844T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL05791430T 2004-10-01 2005-10-03 Zastosowanie [d-meala]3-[etval]4-cyklosporyny do leczenia zakażenia wirusem zapalenia wątroby typu c PL1793844T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2004003205 2004-10-01
EP05791430A EP1793844B1 (en) 2004-10-01 2005-10-03 Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection
PCT/IB2005/002940 WO2006038088A1 (en) 2004-10-01 2005-10-03 Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin

Publications (1)

Publication Number Publication Date
PL1793844T3 true PL1793844T3 (pl) 2011-05-31

Family

ID=34959441

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05791430T PL1793844T3 (pl) 2004-10-01 2005-10-03 Zastosowanie [d-meala]3-[etval]4-cyklosporyny do leczenia zakażenia wirusem zapalenia wątroby typu c

Country Status (30)

Country Link
US (3) US7439227B2 (pl)
EP (1) EP1793844B1 (pl)
JP (1) JP4892486B2 (pl)
KR (1) KR101191833B1 (pl)
CN (1) CN101056648B (pl)
AT (1) ATE490778T1 (pl)
AU (1) AU2005290984B2 (pl)
BR (1) BRPI0515494A (pl)
CA (1) CA2580448C (pl)
CY (1) CY1114594T1 (pl)
DE (1) DE602005025232D1 (pl)
DK (1) DK1793844T3 (pl)
EA (1) EA012650B1 (pl)
ES (1) ES2357587T3 (pl)
GE (1) GEP20104960B (pl)
HK (1) HK1104236A1 (pl)
HR (1) HRP20110169T1 (pl)
IL (1) IL182362A0 (pl)
MA (1) MA28950B1 (pl)
MX (1) MX2007003387A (pl)
NZ (1) NZ554412A (pl)
PL (1) PL1793844T3 (pl)
PT (1) PT1793844E (pl)
RS (1) RS51614B (pl)
SG (1) SG139750A1 (pl)
SI (1) SI1793844T1 (pl)
TN (1) TNSN07084A1 (pl)
UA (1) UA88484C2 (pl)
WO (1) WO2006038088A1 (pl)
ZA (1) ZA200702610B (pl)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
WO2006005610A1 (en) 2004-07-14 2006-01-19 Novartis Ag Use of a combination of cyclosporine and pegylated interferon for treating hepatitis c (hcv)
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
JP4735861B2 (ja) 2004-11-22 2011-07-27 アステラス製薬株式会社 新規環状ペプチド化合物
KR20070087624A (ko) * 2004-12-23 2007-08-28 노파르티스 아게 Ｈｃｖ 치료용 조성물
RU2007128098A (ru) * 2004-12-23 2009-01-27 Новартис АГ (CH) Соединения для лечения инфекций, вызываемых вирусами семейства flaviviridae
JP2008546708A (ja) * 2005-06-17 2008-12-25 ノバルティス アクチエンゲゼルシャフト Ｈｃｖにおけるサングリフェリンの使用
CA2623864C (en) 2005-09-30 2014-12-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
EP1933859A2 (en) 2005-09-30 2008-06-25 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
US7872097B2 (en) 2005-10-26 2011-01-18 Astellas Pharma Inc. Cyclic peptide compounds
NZ571826A (en) 2006-04-11 2012-01-12 Novartis Ag HCV/HIV inhibitors and their uses
ES2361635T3 (es) 2006-05-19 2011-06-20 Scynexis, Inc. Ciclosporinas para el tratamiento y prevención de trastornos oculares.
CN101557819A (zh) * 2006-10-12 2009-10-14 诺瓦提斯公司 修饰的环孢素的用途
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
ES2396170T3 (es) 2007-05-02 2013-02-19 Astellas Pharma Inc. Nuevos compuestos péptídicos ciclicos
CA2700536A1 (en) 2007-09-26 2009-04-02 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009098533A1 (en) * 2008-02-08 2009-08-13 Debiopharm Sa Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy
JP5820722B2 (ja) 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
NZ593204A (en) * 2008-11-06 2013-02-22 Debio Rech Pharma Sa Cycloundecadepsipeptide compounds and use of said compounds as a medicament
JP5780969B2 (ja) 2008-12-31 2015-09-16 サイネクシス，インコーポレーテッド シクロスポリンａの誘導体
NZ594755A (en) 2009-01-30 2013-12-20 Enanta Pharm Inc Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
EP2509615A1 (en) 2009-12-09 2012-10-17 Scynexis, Inc. Novel cyclic peptides
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2011141891A1 (en) 2010-05-12 2011-11-17 Debio Recherche Pharmaceutique S.A. Use of cycloundecadepsipeptide compounds
US9217015B2 (en) 2010-07-16 2015-12-22 S&T Global Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
US9573978B2 (en) 2010-08-12 2017-02-21 S&T Global, Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
BR112013008078A2 (pt) * 2010-10-05 2016-06-14 Novartis Ag tratamentos de infecção por vírus da hepatite c
KR20130120481A (ko) 2010-10-08 2013-11-04 노파르티스 아게 술파미드 ｎｓ3 억제제의 비타민 ｅ 제제
CN105381450A (zh) * 2010-11-30 2016-03-09 诺华有限公司 丙型肝炎病毒感染的新疗法
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
JO3337B1 (ar) * 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
JP2014509628A (ja) 2011-03-31 2014-04-21 ノバルティス アーゲー Ｃ型肝炎ウイルス感染症を治療するためのアリスポリビル
TW201247216A (en) 2011-04-01 2012-12-01 Novartis Ag Treatment for infection with Hepatitis B virus alone or in combination with Hepatitis delta virus and associated liver diseases
MA35029B1 (fr) * 2011-04-13 2014-04-03 Novartis Ag Traitement de l'infection par le virus de l'hépatite c avec l'alisporivir
EP2760461A1 (en) 2011-09-27 2014-08-06 Novartis AG Alisporivr for treatment of hepatis c virus infection
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN103826627B (zh) 2011-10-21 2016-02-24 艾伯维公司 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途
TW201350127A (zh) 2012-05-07 2013-12-16 Novartis Ag Ｃ型肝炎病毒感染之新治療方法
AR090964A1 (es) * 2012-05-09 2014-12-17 Novartis Ag Proceso para la elaboracion de undecapeptidos ciclicos
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
SG11201601274QA (en) 2013-08-26 2016-03-30 Enanta Pharm Inc Cyclosporin analogues for preventing or treating hepatitis c
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CN110799523A (zh) 2017-05-12 2020-02-14 中外制药株式会社 用于制备环状有机化合物的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
ES2255275T3 (es) * 1998-07-01 2006-06-16 Debiopharm S.A. Nueva ciclosporina con perfil de actividad mejorado.
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PT1793844E (pt) 2011-03-10
CY1114594T1 (el) 2016-10-05
EP1793844B1 (en) 2010-12-08
BRPI0515494A (pt) 2008-07-29
MA28950B1 (fr) 2007-10-01
GEP20104960B (en) 2010-04-26
SI1793844T1 (sl) 2011-05-31
US20090081164A1 (en) 2009-03-26
KR20070073761A (ko) 2007-07-10
US20060252675A1 (en) 2006-11-09
SG139750A1 (en) 2008-02-29
CN101056648B (zh) 2012-08-15
HK1104236A1 (en) 2008-01-11
UA88484C2 (ru) 2009-10-26
AU2005290984B2 (en) 2010-09-09
DE602005025232D1 (de) 2011-01-20
AU2005290984A1 (en) 2006-04-13
CN101056648A (zh) 2007-10-17
RS51614B (en) 2011-08-31
IL182362A0 (en) 2007-07-24
CA2580448C (en) 2012-09-18
CA2580448A1 (en) 2006-04-13
JP2008514690A (ja) 2008-05-08
NZ554412A (en) 2011-01-28
HRP20110169T1 (hr) 2011-04-30
WO2006038088A1 (en) 2006-04-13
ATE490778T1 (de) 2010-12-15
JP4892486B2 (ja) 2012-03-07
TNSN07084A1 (en) 2008-06-02
EA200700725A1 (ru) 2007-10-26
US7772184B2 (en) 2010-08-10
USRE43371E1 (en) 2012-05-08
ES2357587T3 (es) 2011-04-27
US7439227B2 (en) 2008-10-21
MX2007003387A (es) 2007-05-23
ZA200702610B (en) 2008-08-27
KR101191833B1 (ko) 2012-10-16
DK1793844T3 (da) 2011-03-21
EP1793844A1 (en) 2007-06-13
EA012650B1 (ru) 2009-12-30

Similar Documents

Publication Publication Date Title
PL1793844T3 (pl) Zastosowanie [d-meala]3-[etval]4-cyklosporyny do leczenia zakażenia wirusem zapalenia wątroby typu c
WO2005121138A3 (en) Heterotricyclic compounds for use as hcv inhibitors
WO2005123128A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
WO2005102392A3 (en) Combinations for treating hiv infection
WO2001091728A3 (en) Nanoemulsion formulations
WO2006096774A3 (en) Composition and methods for delivering carbon monoxide (co) and nitric ozide (no) co to tissue using heme proteins as carriers
WO2005115417A3 (en) Polycationic antimicrobial therapeutic
TW200640487A (en) Combination of XOLAIR with immunosuppressive agent
WO2006034001A3 (en) Methods of treating hiv infection
WO2007022219A3 (en) Dental composition comprising enzyme
SG149872A1 (en) Antagonists of the bradykinin b1 receptor
WO2008105826A3 (en) Compositions compromising lysostaphin variants and methods of using the same
WO2005094424A3 (en) Use of the pro-peptide domain of lysyl oxidase as a therapeutic agent
WO2005002522A3 (en) Compositions and methods for treating tissue ischemia
WO2004078927A3 (en) Progenitor cells and methods of using same
WO2008051565A3 (en) A drug-release composition having a therapeutic carrier
WO2005091754A3 (en) Novel cyclopentenedione antifungal compounds and methods for their use
WO2007022140A3 (en) Methods of improving cardiac function and attenuating and/or preventing cardiac remodeling with hsp20
CU20070072A7 (es) Uso de [d-meala]3-[etval]4-ciclosporina para el tratamiento de infección por hepatitis c y composición farmacéutica que comprende la [d-meala]3-[etval]4-ciclosporina
EP1252897A4 (en) MEDICINES FOR GENE THERAPY
WO2005082054A3 (en) Combinations for the treatment of fungal infections
WO2005000239A3 (en) Lyase treatment for p. carinii
UA93036C2 (ru) Лактамные соединения и применение в качестве фармацевтических препаратов
WO2007065032A3 (en) Compounds and methods for inhibiting viral entry
Kyff Have You Seen the Tree?